IPO Window Widening for Biotech Firms
New Funding Cycle Seems Possible, But Analysts Warn of Oversaturation

BY MARION WEBB

The biotechnology industry's hopes for more initial public offerings continues to rise...

Take 1 minute to subscribe and you'll get this story immediately, plus:

Already a subscriber? Sign in

  • 52 weekly issues
  • Subscriber-only digital content every business day, plus full access to SDBJ.com archives
  • Book of Lists — the most comprehensive business resource in San Diego
  • San Diego 500 — influential business leaders you need to know
Yours for only $129